Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Azacitidine 4fludarabine 3venetoclax 2bisantrene 2Cyclophosphamide 2Clofarabine 2vosaroxin 1treosulfan 1liposomal amphotericin B 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1Thalidomide 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Interleukin-2 1Idarubicin 1Human Papillomavirus Recombinant Vaccine nonavalent 1Filgrastim 1Everolimus 1Dexamethasone 1Decitabine 1Daunorubicin 1Dasatinib 1Cytarabine 1Cyclosporine 1Control Groups 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Leukemia, Myeloid, Acute × Thalidomide × Clear all
NCT06256627 2024-02-13

The Maintenance Treatment of "ITIVA" in AML Patients

Henan Cancer Hospital

Phase NA Recruiting
130 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡